IP Library Granted Patent US 10,952,994
Granted Patent B2
US 10,952,994 · App. 16/040,160 · Granted Mar 23, 2021

Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases

Inventor: Jeffrey M. Melin (Meadowbrook, PA)
A61K31/436A61K9/0014A61K9/0087A61K9/06A61K31/155A61K31/519A61K47/10A61K2300/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,952,994
App. No.
16/040,160
Granted
Mar 23, 2021
Kind
B2
Abstract

A formulation, especially one that is topically administered, comprising a combination of rapamcycin and metformin in a molar ratio of about 20:1, 10:1, 5:1, 4:1, 3:1, or 1:1. The topical formulation may be a gel, an ointment, a cream or a lotion. The topical formulation may be used to treat a condition or disease of the skin or eye, wherein the condition or disease is associated with mTORC1 activation.

Claims (13)

1. A composition for topical administration comprising a combination of rapamycin and metformin, wherein the rapamycin is present in an amount in a range of about 0.01% to about 4.0% by weight and the metformin is present in an amount in a range of about 0.00007% to about 2.0% by weight, wherein the molar ratio of rapamycin to metformin is in the range of about 20:1 to about 1:1.

2. The composition of claim 1 , wherein the rapamycin is present in an amount in a range of about 0.1% to about 3.5% and the metformin in present in an amount in a range of about 0.002% to about 1.0% by weight.

3. The composition of claim 1 , wherein the rapamycin in present in an amount of up to about 3.5% by weight and the metformin is present in an amount of up to about 2.0% by weight.

4. The composition of claim 1 , wherein the amount of rapamycin is less than about 2.0% by weight.

5. The composition of claim 1 , wherein the amount of metformin is less than about 1.5% by weight.

6. The composition of claim 1 , wherein the composition is in a form selected from a gel, an ointment, a cream, a lotion, or liquid solution.

7. The composition of claim 1 , wherein the composition is in a form for topical mucosal administration.

8. The composition of claim 7 , wherein the composition is in a form selected from drops or aerosols.

9. The composition of claim 1 , wherein the molar ratio of rapamycin to metformin is in the range of about 15:1 to about 1:1.

10. The composition of claim 1 , wherein the molar ratio of rapamycin to metformin is in the range of about 10:1 to about 4:1.

11. The composition of claim 1 , wherein the molar ratio of rapamycin to metformin is in the range of about 5:1 to about 1:1.

12. The composition of claim 1 , wherein the molar ratio of rapamycin to metformin is in the range of about 5:1 to about 3:1.

13. The composition of claim 1 , wherein the molar ratio of rapamycin to metformin is in the range of about 5:1 to 4:1.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2021
From: MELIN, JEFFREY M.
To: JMM LICENSING LLC
Reel/Frame 057426/0207 →
Continuity (5)
Continuation 15828926 · Dec 1, 2017
Continuation 15241312 · Aug 19, 2016
Provisional Application 62259384 · Nov 24, 2015
Provisional Application 62318302 · Apr 5, 2016
Related Publication 20190000815A1 · Jan 3, 2019
Cited By (1)
US 12,409,170